NCT06694883 Critical State of "Remission-Recurrence" of Ulcerative Colitis
| NCT ID | NCT06694883 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Hospital of Traditional Chinese Medicine |
| Condition | Ulcerative Colitis |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-09-19 |
| Primary Completion | 2025-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2024-09-19 with a primary completion date of 2025-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will recruit 100 patients with ulcerative colitis in remission for a 6-month non intervention follow-up observation. During the study, their conditions will be recorded truthfully, including general information, disease-related symptoms and signs, inflammatory bowel disease questionnaire, anxiety self-assessment scale, depression self-assessment scale, etc., every month. Collect blood, urine, and stool samples from patients every month for examination. Follow up for each subject until their condition recurs.
Eligibility Criteria
Inclusion Criteria: * Patients who meet the criteria based on the clinical characteristics of ulcerative colitis patients in the "remission recurrence" critical state, combined with clinical symptoms, are diagnosed with ulcerative colitis through imaging, endoscopy, laboratory, and histopathological examinations; * Patients with comprehensive laboratory testing indicators. Exclusion Criteria: * Patients with incomplete case information records; * Patients who have not completed serological tests; * Complications including intestinal obstruction, intestinal perforation, toxic megacolon, and severe local stenosis; * Diagnosed or suspected patients with coexisting uncertain colitis, infectious or ischemic colitis; * Patients with coexisting local or systemic infections, any malignant diseases, or autoimmune diseases; * Merge primary diseases such as respiratory, circulatory, neurological, endocrine, and hematological disorders; * Individuals at risk of developing cancer; * regnant or lactating women.
Contact & Investigator
Shengsheng Zhang, Doctor
PRINCIPAL INVESTIGATOR
Beijing Hospital of Traditional Chinese Medicine
Frequently Asked Questions
Who can join the NCT06694883 clinical trial?
This trial is open to participants of all sexes, studying Ulcerative Colitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06694883 currently recruiting?
Yes, NCT06694883 is actively recruiting participants. Contact the research team at danyan20121027@163.com for enrollment information.
Where is the NCT06694883 trial being conducted?
This trial is being conducted at Dongcheng, China.
Who is sponsoring the NCT06694883 clinical trial?
NCT06694883 is sponsored by Beijing Hospital of Traditional Chinese Medicine. The principal investigator is Shengsheng Zhang, Doctor at Beijing Hospital of Traditional Chinese Medicine. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.